Literature DB >> 25798042

Bivalirudin Versus Heparin: A Fight Far From Finished?: Efficacy, Safety, and Cost Remain Battlegrounds for the Treatment Of ST-Segment Elevation Myocardial Infarction.

Walter Alexander.   

Abstract

A strident debate has been surging in the interventional cardiology community over the triumvirate of efficacy, safety, and cost of bivalirudin compared with heparin for anticoagulation of patients with ST-segment elevation myocardial infarction.

Entities:  

Year:  2015        PMID： 25798042      PMCID： PMC4357354     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  10 in total

1.  Bivalirudin started during emergency transport for primary PCI.

Authors:  Philippe Gabriel Steg; Arnoud van 't Hof; Christian W Hamm; Peter Clemmensen; Frédéric Lapostolle; Pierre Coste; Jurrien Ten Berg; Pierre Van Grunsven; Gerrit Jan Eggink; Lutz Nibbe; Uwe Zeymer; Marco Campo dell' Orto; Holger Nef; Jacob Steinmetz; Louis Soulat; Kurt Huber; Efthymios N Deliargyris; Debra Bernstein; Diana Schuette; Jayne Prats; Tim Clayton; Stuart Pocock; Martial Hamon; Patrick Goldstein
Journal:  N Engl J Med       Date:  2013-10-30       Impact factor: 91.245

2.  The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction.

Authors:  Daniel P Kessler; Eugene Kroch; Mark A Hlatky
Journal:  Am Heart J       Date:  2011-07-26       Impact factor: 4.749

Review 3.  Real-time decision support to guide percutaneous coronary intervention bleeding avoidance strategies effectively changes practice patterns.

Authors:  Craig E Strauss; Brandon R Porten; Ivan J Chavez; Ross F Garberich; Jeffrey W Chambers; Kenneth W Baran; Anil K Poulose; Timothy D Henry
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-11-04

4.  Choice of optimal anticoagulant to support primary PCI: out with the new, in with the old.

Authors:  Sanjay Kaul
Journal:  J Am Coll Cardiol       Date:  2015-01-06       Impact factor: 24.094

5.  Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Martin Fahy; Helen Parise; Roxana Mehran
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

6.  Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.

Authors:  Duane S Pinto; Augustina Ogbonnaya; Steven A Sherman; Patricia Tung; Sharon-Lise T Normand
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-01-10

7.  Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.

Authors:  Natalia Olchanski; Katherine A Slawsky; Stephanie Plent; Carla Kado; Philip L Cyr
Journal:  Hosp Pract (1995)       Date:  2010-11

8.  Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.

Authors:  Gregg W Stone; Roxana Mehran; Patrick Goldstein; Bernhard Witzenbichler; Arnoud Van't Hof; Giulio Guagliumi; Christian W Hamm; Philippe Généreux; Peter Clemmensen; Stuart J Pocock; Bernard J Gersh; Debra Bernstein; Efthymios N Deliargyris; Philippe Gabriel Steg
Journal:  J Am Coll Cardiol       Date:  2015-01-06       Impact factor: 24.094

9.  Bivalirudin during primary PCI in acute myocardial infarction.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Ajay J Kirtane; Helen Parise; Roxana Mehran
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

10.  Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).

Authors:  Gregg W Stone; Tim Clayton; Efthymios N Deliargyris; Jayne Prats; Roxana Mehran; Stuart J Pocock
Journal:  J Am Coll Cardiol       Date:  2013-10-16       Impact factor: 24.094
  10 in total
  1 in total

Review 1.  New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?

Authors:  María Asunción Esteve-Pastor; Diana Hernández-Romero; Mariano Valdés; Francisco Marín
Journal:  Molecules       Date:  2016-02-27       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.